Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.

ABSTRACT:

Background

Sodium-glucose cotransporter-2 inhibitors improve heart failure-related outcomes. The mechanisms underlying these benefits are not well understood, but diuretic properties may contribute. Traditional diuretics such as furosemide induce substantial neurohormonal activation, contributing to the limited improvement in intravascular volume often seen with these agents. However, the proximal tubular site of action of the sodium-glucose cotransporter-2 inhibitors may help circumvent these limitations.

Methods

Twenty patients with type 2 diabetes mellitus and chronic, stable heart failure completed a randomized, placebo-controlled crossover study of empagliflozin 10 mg daily versus placebo. Patients underwent an intensive 6-hour biospecimen collection and cardiorenal phe

SUBMITTER: Griffin M 

PROVIDER: S-EPMC7521417 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature